As Executive Chairman of the Board of Antylia Scientific, Bernd leads with a persistent drive toward customer-driven organic and inorganic innovation leading to sustainable and profitable growth.

Bernd served as Chairman and CEO of Antylia Scientific from 2014 through December 2021. Before joining Antylia Scientific, Bernd served as President and CEO of Qualicaps, a provider of capsule manufacturing and processing equipment for pharmaceutical companies, which sold to Mitsubishi Chemical Holdings in 2013.

Prior to Qualicaps, he was Chief Commercial Operations Officer at Life Technologies Corporation, where he was responsible for its $3.5 billion global business. Bernd held prior leadership roles with Invitrogen Corporation (a predecessor of Life Technologies) and with GE Medical Systems.

As CEO of Antylia Scientific, Jon is focused on expanding our product portfolio to include more innovative scientific tools enabling our customers to discover and manufacture new therapeutics, vaccines & diagnostics. Beyond his company-wide leadership responsibilities, Jon oversees strategic planning initiatives for Antylia Scientific (including mergers and acquisitions).

Prior to joining Antylia Scientific in November 2015, Jon co-founded and served as the Executive Vice President of Devicor Medical Products, a GTCR-portfolio company sold to the Danaher Corporation in November 2014. Prior to Devicor, Jon was a Managing Director in the Healthcare group at the Royal Bank of Scotland plc.

Earlier in his career, Jon had numerous roles in Corporate Development and M&A with Cardinal Health, Dresdner Kleinwort Wasserstein (formerly Wasserstein Perella) and Deutsche Bank (formerly BT Wolfensohn).

Evangeline Gonzalez is the President of our Diagnostics Division. She has an extensive background in Life Sciences. Prior to joining Antylia Scientific, Evangeline served as the SVP Strategic Marketing for the Life Sciences Segment (LS) at Becton Dickinson (BD). In this role, she worked with the LS Leadership team to develop the portfolio’s investment strategy and market development plans for the diagnostics, point of care, clinical, and basic research markets.

Before Becton Dickinson, Vangie held numerous roles, including SVP Marketing at Beckman Coulter Diagnostics part of Danaher; Chief Commercial Officer at Advanced Cell Diagnostics; and several roles at Life Technologies such as Chief Marketing Officer Life Sciences, VP of the Protein Analysis Business, VP of the Genetic Analysis Division, and Product Manager. Vangie started her career at Amersham / Pharmacia Biotech in Product Development and R&D.

Vangie holds a BS in Biochemistry and Chemistry and an MBA from San Francisco State University.